- $10.10bn
- $11.65bn
- $2.76bn
- 56
- 17
- 45
- 33
Annual balance sheet for Exact Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,840 | 1,030 | 632 | 778 | 1,038 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 233 | 217 | 158 | 204 | 249 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 2,199 | 1,426 | 982 | 1,194 | 1,571 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 597 | 773 | 862 | 853 | 830 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 4,925 | 6,685 | 6,227 | 6,471 | 5,928 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 633 | 517 | 413 | 515 | 732 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2,690 | 3,297 | 3,184 | 3,326 | 3,526 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 2,236 | 3,388 | 3,043 | 3,145 | 2,402 |
| Total Liabilities & Shareholders' Equity | 4,925 | 6,685 | 6,227 | 6,471 | 5,928 |
| Total Common Shares Outstanding |